The association between weight loss medications and cardiovascular complications

IF 4.2 2区医学 Q1 ENDOCRINOLOGY & METABOLISM Obesity Pub Date : 2024-05-06 DOI:10.1002/oby.24037

Onur Baser, Gabriela Samayoa, Katarzyna Rodchenko, Lauren Isenman, Erdem Baser, Nehir Yapar

{"title":"The association between weight loss medications and cardiovascular complications","authors":"Onur Baser, Gabriela Samayoa, Katarzyna Rodchenko, Lauren Isenman, Erdem Baser, Nehir Yapar","doi":"10.1002/oby.24037","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Objective</h3>\n \n <p>Obesity and its cardiovascular complications are major causes of morbidity and mortality. Little is known in real-world settings about the effect of newly approved antiobesity medications (AOMs) on cardiovascular complications among patients with obesity.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>This retrospective cohort study examined the association between newly approved AOM use and cardiovascular events among Medicare patients with obesity using data from 2020 to 2022. Patient age, gender, comorbidity scores, socioeconomic status, and baseline cardiovascular comorbidities were compared descriptively. Subgroup analysis compared variables by medication type. Relative risk and absolute risk of cardiovascular disease (CVD) events were estimated using Cox and Aalen regression models.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>The analysis included 5926 patients treated with semaglutide and tirzepatide, including Ozempic (5404 patients), Wegovy (375 patients), or Mounjaro (147 patients). Hypertension, type 2 diabetes, and hyperlipidemia were the most common comorbidities. For patients with AOMs, less incidence of heart failure (4.89% vs. 6.13%, <i>p</i> < 0.0001), atrial fibrillation (3.83% vs. 5.17%, <i>p</i> < 0.0001), arrhythmia (3.59% vs. 4.14%, <i>p</i> < 0.0153), and peripheral vascular disease (3.44% vs. 2.94%, <i>p</i> < 0.0395) was found versus patients without AOMs. Patients receiving AOMs showed an 8% risk reduction in any CVD. Protective effect on CVD was apparent over the first 375 days.</p>\n </section>\n \n <section>\n \n <h3> Conclusions</h3>\n \n <p>Results suggest that utilization of AOMs effectively alleviates the high prevalence of CVD.</p>\n </section>\n </div>","PeriodicalId":215,"journal":{"name":"Obesity","volume":null,"pages":null},"PeriodicalIF":4.2000,"publicationDate":"2024-05-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/oby.24037","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Obesity","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/oby.24037","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}

引用次数: 0

Abstract

Objective

Obesity and its cardiovascular complications are major causes of morbidity and mortality. Little is known in real-world settings about the effect of newly approved antiobesity medications (AOMs) on cardiovascular complications among patients with obesity.

Methods

This retrospective cohort study examined the association between newly approved AOM use and cardiovascular events among Medicare patients with obesity using data from 2020 to 2022. Patient age, gender, comorbidity scores, socioeconomic status, and baseline cardiovascular comorbidities were compared descriptively. Subgroup analysis compared variables by medication type. Relative risk and absolute risk of cardiovascular disease (CVD) events were estimated using Cox and Aalen regression models.

Results

The analysis included 5926 patients treated with semaglutide and tirzepatide, including Ozempic (5404 patients), Wegovy (375 patients), or Mounjaro (147 patients). Hypertension, type 2 diabetes, and hyperlipidemia were the most common comorbidities. For patients with AOMs, less incidence of heart failure (4.89% vs. 6.13%, p < 0.0001), atrial fibrillation (3.83% vs. 5.17%, p < 0.0001), arrhythmia (3.59% vs. 4.14%, p < 0.0153), and peripheral vascular disease (3.44% vs. 2.94%, p < 0.0395) was found versus patients without AOMs. Patients receiving AOMs showed an 8% risk reduction in any CVD. Protective effect on CVD was apparent over the first 375 days.

Conclusions

Results suggest that utilization of AOMs effectively alleviates the high prevalence of CVD.

Abstract Image

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

减肥药物与心血管并发症之间的关系。

目的：肥胖症及其心血管并发症是发病和死亡的主要原因：肥胖症及其心血管并发症是发病和死亡的主要原因。在现实世界中，人们对新批准的抗肥胖药物（AOMs）对肥胖症患者心血管并发症的影响知之甚少：这项回顾性队列研究利用 2020 年至 2022 年的数据，研究了新批准的抗肥胖药物的使用与医保肥胖症患者心血管事件之间的关系。对患者的年龄、性别、合并症评分、社会经济状况和心血管合并症基线进行了描述性比较。分组分析比较了不同药物类型的变量。使用 Cox 和 Aalen 回归模型估算了心血管疾病（CVD）事件的相对风险和绝对风险：分析纳入了5926名接受过塞马鲁肽和替扎帕肽治疗的患者，包括Ozempic（5404名患者）、Wegovy（375名患者）或Mounjaro（147名患者）。高血压、2 型糖尿病和高脂血症是最常见的合并症。在使用 AOMs 的患者中，心力衰竭的发生率较低（4.89% 对 6.13%，p 结论：AOMs 的使用率较高：结果表明，使用 AOMs 可以有效缓解心血管疾病的高发病率。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Obesity 医学-内分泌学与代谢

CiteScore

11.70

自引率

1.40%

发文量

261

审稿时长

2-4 weeks

期刊介绍： Obesity is the official journal of The Obesity Society and is the premier source of information for increasing knowledge, fostering translational research from basic to population science, and promoting better treatment for people with obesity. Obesity publishes important peer-reviewed research and cutting-edge reviews, commentaries, and public health and medical developments.